Evidence map›Paper›PMID 24950050›Full record

ArticleToxicon : official journal of the International Society on Toxinology2014

Prevention and treatment of Clostridium perfringens epsilon toxin intoxication in mice with a neutralizing monoclonal antibody (c4D7) produced in Nicotiana benthamiana.

J P Garcia, J Beingesser, O Bohorov, N Bohorova, C Goodman, D Kim, M Pauly, J Velasco, K Whaley, L Zeitlin and 2 more

Open access · greenAbstract read
In one paragraph

Article in Toxicon : official journal of the International Society on Toxinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Hydroponic Treatment ofFrontiers in plant science · 2018
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

J P GarciaCalifornia Animal Health and Food Safety Laboratory System, San Bernardino Branch, School of Veterinary Medicine, University of California, Davis, San Bernardino, CA 92408, USA.
J BeingesserCalifornia Animal Health and Food Safety Laboratory System, San Bernardino Branch, School of Veterinary Medicine, University of California, Davis, San Bernardino, CA 92408, USA.
O BohorovMapp Biopharmaceutical, Inc., San Diego, CA, USA.
N BohorovaMapp Biopharmaceutical, Inc., San Diego, CA, USA.
C GoodmanMapp Biopharmaceutical, Inc., San Diego, CA, USA.
D KimMapp Biopharmaceutical, Inc., San Diego, CA, USA.
M PaulyMapp Biopharmaceutical, Inc., San Diego, CA, USA.
J VelascoMapp Biopharmaceutical, Inc., San Diego, CA, USA.
K WhaleyMapp Biopharmaceutical, Inc., San Diego, CA, USA.
L ZeitlinMapp Biopharmaceutical, Inc., San Diego, CA, USA.
C J RoyMicrobiology Division, Tulane National Primate Research Center, Covington, LA, USA.
F A UzalCalifornia Animal Health and Food Safety Laboratory System, San Bernardino Branch, School of Veterinary Medicine, University of California, Davis, San Bernardino, CA 92408, USA. Electronic address: fuzal@cahfs.ucdavis.edu.
California State University, San Bernardino · USTulane University · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)U01AI082276 · NIAID · MAPP BIOPHARMACEUTICAL, INC. · PI ZEITLIN, LARRY · 2009 to 2013
$10.0M
An Antibody Immunoprotectant for Category B ToxinsR01AI098774 · NIAID · MAPP BIOPHARMACEUTICAL, INC. · PI ZEITLIN, LARRY · 2012 to 2016
$6.2M
NIAID NIH HHS R01 AI098774NIAID NIH HHS U01 AI082276NIAID NIH HHS U01AI082276NIH HHS P51 OD011104
6 · The paper itself

Abstract

Epsilon toxin (ETX), produced by Clostridium perfringens types B and D, is among the most lethal toxins known. ETX is a potential bioterrorism threat that was listed as a Category B agent by the U.S. Centers for Disease Control until 2012 and it still remains a toxin of interest for several government agencies. We produced a monoclonal antibody (MAb) against ETX (ETX MAb c4D7) in Nicotiana benthamiana and characterized its preventive and therapeutic efficacy in mice. The ETX preparation used was highly lethal for mice (LD50 = 1.6 μg/kg) and resulted in a mean time from inoculation to death of 18 and 180 min when administered intravenously or intraperitoneally, respectively. High lethal challenge resulted in dramatic increases of a variety of pro-inflammatory cytokines in serum, while lower, but still lethal doses, did not elicit such responses. ETX MAb c4D7 was highly effective prophylactically (ED50 = 0.3 mg/kg; ED100 = 0.8 mg/kg) and also provided protection when delivered 15-30 min post-ETX intoxication. These data suggest that ETX MAb c4D7 may have use as a pre- and post-exposure treatment for ETX intoxication.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingBacterial ToxinsCytokinesFemaleLethal Dose 50MaleMiceMice, Inbred BALB CNicotianaAntibodies, MonoclonalAntibodies, NeutralizingBacterial ToxinsClostridium perfringens epsilon-toxinCytokinesEpsilon toxinMonoclonal antibodyNicotiana benthamianaPreventiveTherapeutic

Identifiers

PMID24950050
PMCPMC4119486
OpenAlexW2000514587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.